Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ATYR Atyr Pharma Inc
- Stocks
- Healthcare
- NASDAQ: ATYR
Price (delayed)
$3.27
Market cap
$291.04M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.8
Enterprise value
$291.24M
atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly
Highlights
Atyr Pharma's quick ratio has increased by 46% from the previous quarter and by 32% YoY
ATYR's EPS is up by 11% year-on-year and by 7% since the previous quarter
The company's equity fell by 11% YoY but it rose by 7% QoQ
The revenue has shrunk by 100% QoQ and by 100% YoY
The company's gross profit has shrunk by 100% QoQ and by 100% YoY
Key stats
What are the main financial stats of ATYR
Market
Valuations
Earnings
Shares outstanding
89M
Market cap
$291.04M
Enterprise value
$291.24M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.87
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$67.05M
Net income
-$63.41M
EBIT
-$63.41M
EBITDA
-$62.26M
Free cash flow
-$62.2M
Per share
Balance sheet
Liquidity
EPS
-$0.8
EPS diluted
-$0.8
Free cash flow per share
-$0.72
Book value per share
$0.84
Revenue per share
$0
TBVPS
$1.12
Total assets
$97.25M
Total liabilities
$22.38M
Debt
$12.99M
Equity
$75.05M
Working capital
$72.59M
Debt to equity
0.17
Current ratio
7.79
Quick ratio
7.47
Net debt/EBITDA
0
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-64.8%
Return on equity
-86.9%
Return on invested capital
-74%
Return on capital employed
-73.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ATYR stock price
How has the Atyr Pharma stock price performed over time
Intraday
9%
1 week
-0.3%
1 month
8.28%
1 year
69.43%
YTD
-9.67%
QTD
8.28%
Financial performance
How have Atyr Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$67.05M
Net income
-$63.41M
Gross margin
N/A
Net margin
N/A
The revenue has shrunk by 100% QoQ and by 100% YoY
The company's gross profit has shrunk by 100% QoQ and by 100% YoY
The net income has contracted by 18% YoY
Atyr Pharma's operating income has decreased by 14% YoY
Price vs fundamentals
How does ATYR's price correlate with its fundamentals
Growth
What is Atyr Pharma's growth rate over time
Valuation
What is Atyr Pharma stock price valuation
P/E
N/A
P/B
3.87
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ATYR's EPS is up by 11% year-on-year and by 7% since the previous quarter
ATYR's P/B is 142% above its 5-year quarterly average of 1.6 and 38% above its last 4 quarters average of 2.8
The company's equity fell by 11% YoY but it rose by 7% QoQ
The revenue has shrunk by 100% QoQ and by 100% YoY
Efficiency
How efficient is Atyr Pharma business performance
The return on equity has dropped by 53% year-on-year and by 2.2% since the previous quarter
The ROA has contracted by 48% YoY and by 3.2% from the previous quarter
The company's return on invested capital fell by 47% YoY and by 3.4% QoQ
Dividends
What is ATYR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ATYR.
Financial health
How did Atyr Pharma financials performed over time
Atyr Pharma's quick ratio has increased by 46% from the previous quarter and by 32% YoY
The current ratio has grown by 42% from the previous quarter and by 28% YoY
The debt is 83% less than the equity
The company's equity fell by 11% YoY but it rose by 7% QoQ
ATYR's debt to equity is down by 11% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.